MedTrace Logo

A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT04536688 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2021-12-15

No results posted yet for this study

Summary

Primary Objective

• To assess the dose response relationship between RGLS4326 and ADPKD biomarkers

Secondary Objectives

* To characterize the pharmacokinetic (PK) properties of RGLS4326 in plasma and urine
* To assess the safety and tolerability of RGLS4326

Conditions

  • Polycystic Kidney Disease, Autosomal Dominant

Interventions

DRUG

RGLS4326

Solution for subcutaneous injection

Sponsors & Collaborators

  • Regulus Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Karl Cremer, PharmD · Regulus Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-13
Primary Completion
2021-11-12
Completion
2021-11-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04536688 on ClinicalTrials.gov